Trial Profile
A Phase 2 Open-label, Multicenter, Randomized, Multidrug Platform Study of Neoadjuvant Durvalumab Alone or in Combination With Novel Agents in Subjects With Resectable, Early-stage (I [> 2 cm] to IIIA) Non-small Cell Lung Cancer (NeoCOAST)
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 27 Mar 2023
Price :
$35
*
At a glance
- Drugs Danvatirsen (Primary) ; Durvalumab (Primary) ; Monalizumab (Primary) ; Oleclumab (Primary)
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
- Acronyms NeoCOAST
- Sponsors AstraZeneca; MedImmune
- 14 Nov 2022 According to an Innate Pharma media release, AstraZeneca presented data from the trial in an oral presentation at the European Society for Medical Oncology (ESMO) 2022 congress.
- 13 Sep 2022 Results presented at the 47th European Society for Medical Oncology Congress
- 01 Sep 2022 According to Innate Pharma media release, the company announced that it will present the design of the phase Ib study, ANKETtm platform, oral presentation on design multispecific antibodies: ANKET for antigen-specific activation of NK cells and platform study of neoadjuvant durvalumab alone or combined with novel agents in patients with resectable, early stage non-small cell lung cancer.